BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 12656651)

  • 1. Nonsteroidal anti-inflammatory drugs and heart failure.
    Bleumink GS; Feenstra J; Sturkenboom MC; Stricker BH
    Drugs; 2003; 63(6):525-34. PubMed ID: 12656651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective inhibitors of type 2 cyclooxygenase: less renal effects than the classical non-steroidal anti-inflammatory agents].
    Chiolero A; Würzner G; Burnier M
    Nephrologie; 2000; 21(8):425-30. PubMed ID: 11213386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2 inhibitors and the kidney.
    Appel GB
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S37-40. PubMed ID: 11695250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of cyclooxygyenase-2-selective inhibitors.
    Brater DC
    J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S15-20; discussion S21-3. PubMed ID: 11992745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.
    Noroian G; Clive D
    Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of COX-2-selective inhibitors.
    Brater DC; Harris C; Redfern JS; Gertz BJ
    Am J Nephrol; 2001; 21(1):1-15. PubMed ID: 11275626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
    Savage R
    Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 inhibition and renal physiology.
    Harris RC
    Am J Cardiol; 2002 Mar; 89(6A):10D-17D. PubMed ID: 11909556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 selective inhibitors and the kidney.
    Breyer MD; Hao C; Qi Z
    Curr Opin Crit Care; 2001 Dec; 7(6):393-400. PubMed ID: 11805541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Komers R; Anderson S; Epstein M
    Am J Kidney Dis; 2001 Dec; 38(6):1145-57. PubMed ID: 11728945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.
    Gambaro G; Perazella MA
    J Intern Med; 2003 Jun; 253(6):643-52. PubMed ID: 12755960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal effects of nonselective NSAIDs and coxibs.
    Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI53-8. PubMed ID: 12086295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent development of selective cyclooxygenase-2 inhibitors].
    Kawai S
    Nihon Rinsho; 2002 Dec; 60(12):2370-7. PubMed ID: 12510364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal tolerance of selective inhibitors of cyclooxygenase type 2].
    Deray G
    Presse Med; 2001 Oct; 30(30):1507-12. PubMed ID: 11712212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.